GB2298198A — Pyrrolo-pyridine derivatives
Assigned to Organon Pharma UK Ltd · Expires 1996-08-28 · 30y expired
What this patent protects
A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety and at the 2-position by an alkyl, alkoxy, halogen, cyano or trifluoromethyl substituent, are antagonists of dopamine receptor subtypes in the brain, being poten…
USPTO Abstract
A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety and at the 2-position by an alkyl, alkoxy, halogen, cyano or trifluoromethyl substituent, are antagonists of dopamine receptor subtypes in the brain, being potent antagonists of the human dopamine D 4 receptor subtype and having a selective affinity for the D 4 subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of clinical conditions requiring the administration of a selective antagonist of the dopamine D 4 receptor subtype.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.